文献速递淋巴瘤

达沙替尼治疗复发或难治性非霍奇金淋巴瘤的I/II期研究及探索性基因组分析

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.
PubMed 文献 · Br J Haematol · 2018-12-05

这项I/II期试验评估达沙替尼在33例复发/难治性非霍奇金淋巴瘤(NHL)中的安全性和疗效,并进行分析性基因组研究。可评估患者的客观缓解率为29%(7/24),临床获益率为71%(17/24);中位无进展生存期3个月,中位总生存期22.4个月。胸腔积液是最常见的非血液学毒性;两例持续完全缓解的PTCL-NOS患者携带LRRK2共同突变。

要点

  • 达沙替尼在复发/难治性NHL中客观缓解率29%(7/24),临床获益率71%(17/24)。
  • 中位无进展生存期3个月,中位总生存期22.4个月(32例有结局数据)。
  • 两例持续完全缓解者均为PTCL-NOS,携带LRRK2共同突变。

核心结论

  • 达沙替尼在复发/难治性NHL中显示出适度的抗肿瘤活性,两例PTCL-NOS患者获得持续完全缓解。

研究设计与样本

  • I/II期试验,纳入33例既往至少接受过一种治疗的复发/难治性NHL患者。
  • 最常见亚型为弥漫大B细胞淋巴瘤(24%)、1/2级滤泡性淋巴瘤(21%)和外周T细胞淋巴瘤非特指型(PTCL-NOS;21%)。
  • 多数患者既往治疗强度大,42%接受过四种以上既往治疗,67%曾暴露于利妥昔单抗,24%曾接受自体移植。

主要发现

  • 可评估患者的客观缓解率为29%(7/24),临床获益率为71%(17/24)。
  • 32例有结局数据的患者中,中位无进展生存期为3个月,中位总生存期为22.4个月。
  • 两例持续完全缓解患者均为PTCL-NOS组织学亚型。
  • 副作用特征与既往研究一致,胸腔积液是最常见的非血液学毒性。
  • 探索性基因组分析显示,两例持续缓解的PTCL-NOS患者携带LRRK2共同突变,复发/难治性滤泡性淋巴瘤中FOXO1突变高发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed or refractory non-Hodgkin lymphomas (NHLs) often carry poor prognosis and pose management challenges. We evaluated the safety and efficacy of dasatinib, a broad-spectrum multi-kinase inhibitor in relapsed/refractory NHL with correlative genomic analysis in a Phase I/II trial. The study included 33 patients with various sub-types of NHL who had received at least one prior therapy. The most common sub-types were diffuse large B-cell lymphoma (24%), follicular lymphoma, grade 1/2 (21%) and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS; 21%). Most patients were heavily pre-treated, including 42% with more than four prior therapies, 67% with rituximab exposure and 24% with prior autologous transplant. In this cohort, dasatinib showed modest activity in evaluable patients with an objective response rate of 29% (7/24) and clinical benefit rate of 71% (17/24). In 32 patients with outcome data, median progression-free survival was 3 months and median overall survival was 22·4 months. There were two patients with sustained complete responses, both with PTCL-NOS histology. The side effect profile was consistent with prior studies, with pleural effusion being the most common non-haematological toxicity. Exploratory genomic analysis showed two cases of PTCL-NOS with sustained response had a common mutation in LRRK2 and high prevalence of FOXO1 mutation in relapsed/refractory follicular lymphoma.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Umakanthan JM, Iqbal J, Batlevi CL, et al. Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma. Br J Haematol. 2018. PMID: 30520026. doi:10.1111/bjh.15702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。